Founded in 1958, Labiana Health has evolved from its origins in animal health to become an international pharmaceutical group listed on BME Growth, with a diversified business model based on combining animal health and human health, a portfolio of proprietary products, and CDMO services.

The company operates an integrated platform covering the entire pharmaceutical value chain, from development and manufacturing to regulatory registration and international commercialization.

 

Labiana conducts its activity through two complementary lines, combining a base of recurring revenues derived from its CDMO activity with the progressive development of its own product portfolio:

CDMO Services — Recurrence and Revenue Visibility

Labiana provides comprehensive development, manufacturing, and regulatory support services for more than 300 international pharmaceutical groups. This business is characterized by long-term contracts, high recurrence, and significant barriers to entry resulting from regulatory complexity and GMP standards.

The company has specialized industrial capabilities in high value-added technologies, including:

• Sterile injectables (including one of the largest plants in Europe, located in Terrassa)
• Lyophilized products
• Oral solids and other complex pharmaceutical forms

It also holds regulatory authorizations for the manufacture of highly demanding medicines, including psychotropic drugs, narcotics, hormones, and products intended for clinical trials, further strengthening its barriers to entry and positioning in specialized segments.

Proprietary Product Portfolio — Development and Growth

Labiana markets more than 50 medicines in over 114 countries. In the human health area, Fosfomycin Trometamol stands out, with a consolidated position in international markets and growth potential in new territories.